NASDAQ$RDNT
Radnet Inc · Q4 2021 earnings
Q4 2021 earnings · · Investor relations
Briefing
RadNet's revenue increased by 8.0% and Adjusted EBITDA by 7.5% compared to Q4 2020, despite being impacted by the Omicron surge of COVID-19.
RadNet reported an 8.0% increase in revenue and a 7.5% increase in Adjusted EBITDA for Q4 2021 compared to the same period in 2020, despite a $4 million revenue and $3 million Adjusted EBITDA impact from the Omicron surge. The company's strong financial position allowed for investments in differentiating facilities, with a cash balance of over $134 million and a net debt leverage ratio under 3.0 times Adjusted EBITDA.
- Revenue increased by 8.0% and Adjusted EBITDA by 7.5% compared to Q4 2020.
- The Omicron surge reduced revenue by over $4 million and Adjusted EBITDA by approximately $3 million.
- Cash balance at year-end 2021 was over $134 million, with a net debt leverage ratio under 3.0 times Adjusted EBITDA.
- Completed acquisitions of Aidence Holding B.V. and Quantib B.V., two Artificial Intelligence companies.
Headline financials
Revenue & EPS history
Radnet · Revenue · Quarterly
$333M
Forward guidance
RadNet anticipates growth in 2022 from same-center growth, reimbursement increases, new and expanded health system joint ventures, and acquisitions completed in 2021. The guidance excludes anticipated losses from the AI division of $12 million to $17 million.
Tailwinds
- Growth from same-center activities.
- Reimbursement increases from private and capitated payers.
- New and expanded health system joint ventures.
- Contribution from acquisitions completed in 2021.
- Exclusion of AI division losses provides transparency.
Headwinds
- 2021 Adjusted EBITDA was positively impacted by provider relief proceeds and employee retention credit.
- Estimated $7.4 million impact of Medicare reimbursement reductions for 2022.
- Approximately $15 million of additional salaries and wages expense due to a tighter labor market.
- Guidance excludes any new acquisitions or new health system joint ventures during 2022.
- AI division losses are anticipated due to the timing of FDA approvals and commercialization.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q4 2021
+0.8%
Avg return
Earnings day
+0.3%
Avg return
5 days after
+4.9%
Avg return
30 days after
51%
33 / 65 earnings
Positive
+22.5%
Q4 2020
Best reaction
-17.3%
Q1 2015
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -4.1% | -10.1% | — | |
| Q4 2025 | +7.7% | -13.1% | -20.8% | |
| Q3 2025 | +3.4% | -4.0% | -1.5% | |
| Q1 2025 | +2.5% | +9.7% | +6.4% | |
| Q4 2024 | -3.7% | -7.8% | -14.2% | |
| Q3 2024 | +19.1% | +9.7% | +8.8% | |
| Q2 2024 | +3.7% | +3.6% | +5.0% | |
| Q1 2024 | +2.1% | +6.2% | +16.7% | |
| Q4 2023 | +18.2% | +26.4% | +29.7% | |
| Q3 2023 | +0.1% | -2.1% | +23.0% | |
| Q2 2023 | +0.6% | -0.3% | -5.0% | |
| Q1 2023 | -1.7% | -6.2% | +10.1% | |
| Q4 2022 | +10.8% | +19.1% | +16.3% | |
| Q3 2022 | -5.3% | -4.6% | +16.7% | |
| Q2 2022 | +3.5% | +5.4% | -2.0% | |
| Q1 2022 | -5.9% | -5.9% | +4.9% | |
| Q4 2021 | -7.1% | -7.6% | -9.3% | |
| Q3 2021 | -8.2% | -9.0% | -17.5% | |
| Q2 2021 | -11.7% | -19.9% | -21.0% | |
| Q1 2021 | +3.0% | +1.1% | +42.5% | |
| Q4 2020 | +22.5% | +26.2% | +15.0% | |
| Q3 2020 | +13.9% | +11.0% | +17.6% | |
| Q2 2020 | -1.1% | -2.8% | -12.6% | |
| Q1 2020 | +4.6% | +3.7% | +18.8% | |
| Q4 2019 | -14.2% | -46.9% | -32.9% | |
| Q3 2019 | -2.0% | +11.5% | +22.4% | |
| Q2 2019 | +3.1% | +3.6% | -4.8% | |
| Q1 2019 | +4.1% | +4.3% | -1.2% | |
| Q4 2018 | +9.8% | +2.4% | -5.7% | |
| Q3 2018 | -7.1% | -14.2% | -16.9% | |
| Q2 2018 | +1.1% | +1.1% | -1.8% | |
| Q1 2018 | -2.6% | -2.6% | -3.0% | |
| Q4 2017 | +14.0% | +22.2% | +39.1% | |
| Q3 2017 | -3.4% | -5.3% | -6.8% | |
| Q2 2017 | -1.2% | -1.2% | +37.9% | |
| Q1 2017 | +1.6% | +8.7% | +22.2% | |
| Q4 2016 | -6.1% | -1.7% | +2.6% | |
| Q3 2016 | -2.2% | -2.9% | -8.1% | |
| Q2 2016 | +4.4% | +5.2% | +17.1% | |
| Q1 2016 | -6.7% | — | — | |
| Q4 2015 | -15.0% | — | — | |
| Q3 2015 | -0.8% | — | — | |
| Q2 2015 | +12.3% | — | — | |
| Q1 2015 | -17.3% | — | — | |
| Q4 2014 | -12.1% | — | — | |
| Q3 2014 | -12.4% | — | — | |
| Q2 2014 | +21.3% | — | — | |
| Q1 2014 | +22.2% | — | — | |
| Q4 2013 | +20.1% | — | — | |
| Q3 2013 | -10.2% | — | — | |
| Q2 2013 | -5.1% | — | — | |
| Q1 2013 | -8.4% | — | — | |
| Q4 2012 | +3.6% | — | — | |
| Q3 2012 | -10.3% | — | — | |
| Q2 2012 | +4.1% | — | — | |
| Q1 2011 | +1.0% | — | — | |
| Q1 2012 | +1.0% | — | — | |
| Q4 2011 | -2.7% | — | — | |
| Q4 2009 | -2.7% | — | — | |
| Q3 2010 | -11.6% | — | — | |
| Q3 2011 | -11.6% | — | — | |
| Q4 2010 | +10.5% | — | — | |
| Q2 2010 | +10.5% | — | — | |
| Q2 2011 | +10.5% | — | — | |
| Q1 2010 | -2.7% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro